Targeting osteoblast fatty acid metabolism attenuates skeletal and cardiovascular complications in chronic kidney disease models
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci207322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Petra Simic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Division, Mass General Brigham, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Osteoblasts, Vascular Calcification, Fatty Acids. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Disease, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Chronic kidney disease (CKD) disrupts mineral homeostasis, leading to impaired skeletal mineralization and cardiovascular pathology, yet the mechanism linking these processes remains undefined. Here we identify glycerol-3-phosphate acyltransferase 2 (GPAT2) as a regulator that couples free fatty acid (FFA) partitioning in osteoblasts to systemic phosphate balance. In mouse and human CKD, elevated osteoblast GPAT2 routes FFA away from mitochondrial oxidation, limiting phosphate incorporation into bone, and toward lysophosphatidic acid synthesis, increasing production of the phosphaturic hormone fibroblast growth factor 23 (FGF23). By contrast, osteoblast-specific Gpat2 deletion restores osteoblast FFA oxidation and skeletal phosphate incorporation, lowers circulating phosphate and FGF23, and attenuates vascular calcification and cardiac hypertrophy in CKD. Further, a bone-targeted GPAT inhibitor recapitulates most of these beneficial effects. These findings establish a fundamental role for osteoblast lipid metabolism in mineral homeostasis and identify GPAT2 in bone as a promising therapeutic target for both skeletal and cardiovascular complications of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Division, Mass General Brigham, Boston, Massachusetts, USA.
- Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Pediatrics, Division of Pediatric Nephrology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.
- Department of Molecular Biology and.
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Disease
- National Heart, Lung, and Blood Institute
- American Heart Association
Zitieren
APA
Simic, P., Xie, H., Zhou, W., Fan, Y., Pereira, R. C., Dong, F., Roh, J. D., Salusky, I. B., Singh, C., Goodman, R. P., Khatri, A., & Rhee, E. P. (2026). Targeting osteoblast fatty acid metabolism attenuates skeletal and cardiovascular complications in chronic kidney disease models. Journal of Clinical Investigation. https://doi.org/10.1172/jci207322
Vancouver
Simic P, Xie H, Zhou W, Fan Y, Pereira RC, Dong F, et al. Targeting osteoblast fatty acid metabolism attenuates skeletal and cardiovascular complications in chronic kidney disease models. Journal of Clinical Investigation. 2026. doi:10.1172/jci207322
BibTeX
@article{Simic2026,
author = {Simic, Petra and Xie, Han and Zhou, Wen and Fan, Yu and Pereira, Renata C and Dong, Fangcong and Roh, Jason D and Salusky, Isidro B and Singh, Charandeep and Goodman, Russell P and Khatri, Ashok and Rhee, Eugene P},
title = {Targeting osteoblast fatty acid metabolism attenuates skeletal and cardiovascular complications in chronic kidney disease models},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci207322}
}
EUVIMED